IOVA Iovance Biotherapeutics Inc
Company Analysis
Latest News
Iovance's Melanoma Therapy Shows Promise and Revenue Surges — But Can This Cash-Burning Biotech Reach Profitability Before the Money Runs Out?
Reports emerged that Iovance Biotherapeutics delivered a 41% response rate for its immune-cell cancer therapy in a key melanoma trial, while simultaneously...
Iovance Reports 41% Response Rate for Lifileucel in Melanoma Trial
Iovance Biotherapeutics reported positive interim results from its Phase 2 IOV-COM-202 study of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, in...
🟢 Iovance Biotherapeutics is trading 12% up
Iovance Biotherapeutics is trading 11.76% higher at $14.88 on October 9, 2026, with no clear company-specific announcement identified to explain the move. -...
🟢 Iovance Biotherapeutics is trading 5% up
Iovance Biotherapeutics is trading at $13.94, up 4.73% at 9:59 a.m. ET on October 9, 2026; no clear company-specific catalyst was identified for the rise. -...
🔴 Iovance Biotherapeutics is trading 4.03% down
Iovance Biotherapeutics is trading 4.03% lower at $13.58, with no clear company-specific announcement identified to explain the October 6 move. - Supplied...
🟢 Iovance Biotherapeutics is trading 4.36% up today after lifting 2026 revenue guidance
Iovance Biotherapeutics is trading at $15.08, up 4.36%, extending its September 29 rally after lifting 2026 revenue guidance. - Guidance is now $410–$420...
Iovance Raises Revenue Outlook by $55 Million, but Can a Single Cancer Drug Sustain This Rally
Shares of Iovance Biotherapeutics surged 18.9% to $13.07 on September 29 after the company lifted its full-year 2026 revenue guidance to $410–$420 million, a...
Iovance Biotherapeutics Raises FY2026 Revenue Guidance to $410-$420 Million
Iovance Biotherapeutics has increased its full-year 2026 total revenue guidance, citing strong U.S. demand for its cancer therapies, Amtagvi® (lifileucel) and...
🟢 Iovance Biotherapeutics is trading 18.93% up after lifting 2026 revenue outlook to $410–$420 million
Iovance Biotherapeutics is trading at $13.07, up +18.93%, after raising its 2026 revenue guidance to $410–$420 million. - The new range is $55 million higher...
🟢 Iovance Biotherapeutics is trading 11% up in pre-market; no clear catalyst identified
Iovance Biotherapeutics is trading at $12.15, up 10.55% in pre-market, with no clear catalyst identified. - No company-specific announcement or confirmed...
🟢 Iovance Biotherapeutics is trading 5% up in pre-market
Iovance Biotherapeutics is trading at $11.55, up 5.10%, in pre-market; the immediate reason for the move remains unclear. - No clear company-specific...
Iovance Biotherapeutics Stock Momentum and Valuation Scrutinized After Significant Rally
Iovance Biotherapeutics' stock faces scrutiny over its current valuation. This follows a 421.3% return over the past year. The company is a clinical-stage...
Iovance Wins Goldman Strong-Buy Upgrade as Amtagvi Operations Improve
Goldman Sachs upgraded Iovance Biotherapeutics to a strong-buy rating on Friday. The bank said Amtagvi, Iovance’s only commercialized drug, appears to be...
🟢 Iovance Biotherapeutics is trading 4.17% up today in a technical rebound
Iovance Biotherapeutics is trading 4.17% higher at $10.62; the move appears to reflect a technical rebound or stock-specific trading, without a confirmed fresh...
🔴 Iovance Biotherapeutics is trading 4.04% down today as Nasdaq falls amid firmer yields
Iovance Biotherapeutics is trading 4.04% down at $10.21 as U.S. equities weaken. - The Nasdaq is down 1.03%, with investors reacting to firmer yields, renewed...
🟢 Iovance Biotherapeutics is trading 4.17% up today amid broader biotech-sector momentum
Iovance Biotherapeutics is trading at $10.62, +4.17% on September 22, 2026, amid broader biotech-sector momentum. • Biotech is up 2.07%, supported by positive...
Barclays Sees 52% Upside in Iovance on Lung Cancer Hopes — But Can a $10 Stock Really Deliver?
Shares of Iovance Biotherapeutics surged as much as 10.2% to $10.87 on September 17 after Barclays analyst Etzer Darout raised his price target from $13 to $15...
🟢 Iovance Biotherapeutics is trading 10.16% up today after Barclays raised its price target to $15
Iovance Biotherapeutics is trading 10.16% up at $10.87 after Barclays maintained its Overweight rating and raised its price target from $13 to $15 on September...
🟢 Iovance Biotherapeutics is trading 5.3% up today after Barclays lifted price target to $15
Iovance Biotherapeutics is trading 5.3% up now at $10.44 after Barclays maintained its Overweight rating and raised its price target from $13 to $15 on...
🟢 Iovance Biotherapeutics is trading 4.3% up today
Iovance Biotherapeutics is trading at $9.76, up +4.27%, outperforming the broader biotech sector, which is down 2.11% during the regular session. - No new...